Curaleaf Hits $340M In Q2 Sales; Cannabis Giant Pushes Toward Global Leadership

Jelena MartinovicBy , Featured Writer
Burn After Reading The 30-second intel for operators and investors

Curaleaf posts Q2 revenue of $340.1 million, up 10% year-over-year and 5% sequentially, with domestic sales up 7% and international sales up 26%. Shares trade 8.10% lower at $8.28.

  • Operators: Growth is coming from both domestic and international markets. Curaleaf now has 73 Florida dispensaries, full ownership of Curaleaf International, and has applied to register its medical sites with the DEA.
  • Investors: Revenue and gross margin rise, but adjusted EBITDA margin falls 120 basis points to 20.6%. Net income from continuing operations is $12.5 million and cash is $107 million. Shares fall despite the results.
  • Do now: Compare your own year-over-year revenue growth and margin trends against Curaleaf's 10% growth, 50% gross margin and 20.6% adjusted EBITDA margin to see where you stand.
Short on time? You’re done. Want the numbers?Keep reading ↓

Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) reported on Wednesday that its second-quarter revenue hit $340.1 million. That’s an increase of 10% year-over-year and 5% sequentially.

The cannabis giant revealed domestic revenue grew 7% year-over-year, marking the second consecutive quarter of year-over-year domestic growth. International revenue grew 26% over the same period.

“Our second quarter results reinforce that our ‘Built for Growth’ strategy, a disciplined framework focused on customer centricity, brand building, and operational excellence, is gaining traction across the business,” Chairman and CEO Boris Jordan said in a press release. “We have a strong, cohesive team aligned around one common goal: making Curaleaf the global leader in cannabis.”

Other quarterly business highlights include expansion of Curaleaf’s Florida retail presence to 73 dispensaries and wrapping up the acquisition of the remaining 45% stake in Four20 Pharma, making Curaleaf International, which has a presence in 16 countries across Europe, Australasia and North America, 100% owned.

In addition, Curaleaf applied to register all medical cultivation, processing and dispensing locations with the DEA.

Q2 2026 Financial Highlights

  • Gross profit totaled $169.9 million, with a gross profit margin of 50%, representing an increase of 70 basis points year-over-year.
  • Net income from continuing operations was $12.5 million, or $0.05 per share.
  • Adjusted EBITDA came in positive at $70.1 million, while the adjusted EBITDA margin was 20.6%, a 120-basis-point decrease year-over-year.
  • Total cash and cash equivalents at quarter-end amounted to $107 million.

CURLF Price Action

Curaleaf’s shares traded 8.10% lower at $8.28 per share as of Wednesday.

Related coverage

Image
Jelena Martinovic
August 5, 2026
Covers cannabis news, markets and regulation for IgniteIt. Previously wrote about financial markets for Benzinga and Insider Monkey.
Share: